News | May 28, 2024
AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Currently, Venkat is Lead – Market Access, India at Pfizer
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Sanjeev is currently the Country President for AstraZeneca Malaysia
The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
Subscribe To Our Newsletter & Stay Updated
